Phone: 86-17339854922
Mail: sales20@interlgroup.com
Add: Room 305 , 3/F , Haipai Decoration Office Building , Yudu Avenue , Yuncheng , Shanxi
Edoxaban powder Raw Materials CAS 480449-70-5
Product Overview:
Edoxaban powder Chemical name: N - (5 - chloro pyridine - 2 -) N '- ((1 s, 2 r, 4 s) - 4 - [(dimethyl amino) carbonyl] - 2 - {[(5, 7 - methyl - 4 - four hydrogen thiazole and [5], 4 - c pyridine - 2 - base) carbonyl] amino} cyclohexyl) ethyl diamine, using toluene sulfonate in preparations. Edoxaban is a small molecule oral anticoagulant developed by Daiichi Sankyo Co., LTD., which is a clotting factor X(FXa) inhibitor. During clotting, activated clotting factor X(FXa) activates prothrombin (FII) to become thrombin (FIIa), which promotes fibrin formation and thus thrombosis, so Edoxaban powder has become a prime target for the development of a new generation of anticoagulant drugs.
Edoxaban powder Raw Materials CAS 480449-70-5 Attributes
MF:C24H30ClN7O4S
MW:548.06
EINECS:859-181-7
Specification:Edoxaban powder
Sample:Edoxaban powder
Brand:Edoxaban powder
Appearance: powder
Storage: Cool Dry Place
Brand: chemical Raw Materials
Shelf Life: 2 Years
Test Method: HPLC
Edoxaban powder Raw Materials CAS 480449-70-5 Details
Uses and synthesis of Edoxaban powder
Edoxaban powder Chemical name: N - (5 - chloro pyridine - 2 -) N '- ((1 s, 2 r, 4 s) - 4 - [(dimethyl amino) carbonyl] - 2 - {[(5, 7 - methyl - 4 - four hydrogen thiazole and [5], 4 - c pyridine - 2 - base) carbonyl] amino} cyclohexyl) ethyl diamine, using toluene sulfonate in preparations. Edoxaban is a small molecule oral anticoagulant developed by Daiichi Sankyo Co., LTD., which is a clotting factor X(FXa) inhibitor. During clotting, activated clotting factor X(FXa) activates prothrombin (FII) to become thrombin (FIIa), which promotes fibrin formation and thus thrombosis, so Edoxaban powder has become a prime target for the development of a new generation of anticoagulant drugs.
Applications/Functions of Edoxaban powder
Edoxaban powder is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) after 5-10 days of intravenous anticoagulation. Reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
Physicochemical Property of Edoxaban powder
